Mechanistically, data from solid and hematologic cancers have shown that ATRA can repress NRF2 transcription or prevent its nuclear translocation by promoting its association with the nuclear receptor RARα [121,122], which appears to be independent on the antagonistic formation of heterodimers with RXRα [122]. This evidence concerns the gene NFE2L2 and hematopoietic and lymphoid cell neoplasm.